The objective of this work was to evaluate the safety and efficacy of a recombinant. subunit SARS-CoV-2 animal vaccine in cats against virulent SARS-CoV-2 challenge. Two groups of cats were immunized with two doses of either a recombinant SARS-CoV-2 spike protein vaccine or a placebo. administered three weeks apart. https://bursgaers.shop/product-category/screenprotector/